Mobile

A study of everolimus plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced neuroendocrine cancer of gastrointestinal or lung origin. Klin...

Update Il y a 4 ans
Reference: EUCTR2011-002887-26

A study of everolimus plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced neuroendocrine cancer of gastrointestinal or lung origin. Klinické hodnocení everolimu plus nejlepší podpůrná léčba versus placebo plus nejlepší podpůrná léčba v léčbě pacientů s pokročilými neuroendokrinními nádory gastrointestinálního nebo plicního původu

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

Determinate whether treatment with everolimus plus best supportive care prolongs PFS compared to placebo plus best supportive care in patients with advanced NET of GI or lung origin

Inclusion criteria

  • Advanced neuroendocrine tumor (NET) of GI or lung origin

Links